Lonza Expands Genetix ZYNTEGLO Manufacturing as Gene Therapy Demand Surges

Lonza Group Ltd ( (CH:LONN) ) has issued an announcement.

Lonza and Genetix Biotherapeutics have extended and expanded their long-standing commercial manufacturing agreement for ZYNTEGLO, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia. The renewed deal will increase manufacturing capacity at Lonza’s Houston cell and gene therapy facility to meet rapidly growing patient demand and sustain the therapy’s commercial momentum.

The collaboration, in place since 2013, was instrumental in achieving ZYNTEGLO’s commercial approval in 2022 and its subsequent uptake in the rare disease market. The extended partnership also lays the groundwork for future scale-up of additional Genetix therapies, reinforcing Lonza’s position as a key CDMO in cell and gene therapy and supporting Genetix’s strategy to broaden its manufacturing base and secure reliable supply for its growing portfolio.

ZYNTEGLO is a first-in-class, one-time ex-vivo gene addition therapy that can eliminate the need for regular red blood cell transfusions in eligible beta-thalassemia patients. The therapy, which has received multiple FDA designations, exemplifies the shift toward curative treatments in rare hematologic diseases and highlights how manufacturing partnerships are becoming critical infrastructure for the commercial viability and scalability of advanced gene therapies.

The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF670.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.

More about Lonza Group Ltd

Lonza Group AG is one of the world’s largest contract development and manufacturing organizations, providing development and manufacturing services to pharma and biotech customers across five continents. The Basel-based CDMO generated CHF 6.5 billion in sales and CHF 2.1 billion in CORE EBITDA in 2025, supporting life-saving and life-enhancing therapies with advanced manufacturing technologies.

Genetix Biotherapeutics Inc. is a privately held, commercial-stage biotechnology company focused on genetic therapies for severe rare diseases, including FDA-approved treatments for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy. Headquartered in Somerville, Massachusetts, Genetix aims to scale patient access and improve treatment experiences through curative gene therapies.

Average Trading Volume: 164,262

Technical Sentiment Signal: Hold

Current Market Cap: CHF34.36B

For an in-depth examination of LONN stock, go to TipRanks’ Overview page.